Â鶹Ãâ·Ñ°æÏÂÔØ

Search

Neurological drugs dominate the headlines, and therapeutics from snakes

Ìý

, co-founder and CEO of and Â鶹Ãâ·Ñ°æÏÂÔØBoulder PhD alum of molecular, cellular and developmental biology, is developing appetite-suppressing molecules discovered through python biology that could offer an alternative to GLP-1 drugs with fewer gastrointestinal side effects.

Ìý

Ìý

Ìý

What could you do with a Â鶹Ãâ·Ñ°æÏÂÔØtechnology?

Venture Partners manages a portfolio of over 1,000 technologies from university investigators and partners with entrepreneurs and companies of all sizes—from startups to the Fortune 500—to bring these inventions to market.

Explore Partnership Opportunities

Turn your discovery into real-world impact

Venture Partners helps researchers, inventors and creators take their groundbreaking discoveries every step of the way, from intellectual property (IP) management to market launch.Ìý

More for University Innovators

Ìý

The Newsroom

Subscribe to Newsletters

The InsiderÌýisÌýVenture Partners at Â鶹Ãâ·Ñ°æÏÂÔØBoulder's monthly newsletter featuring theÌýlatest headlines, news, events, opportunities and emerging innovations from the university. We have several editions for our audiences:

ÌýSubscribe to The InsiderÌýÌý

Media Inquiries

For marketing and communication inquiries or news tips, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at Â鶹Ãâ·Ñ°æÏÂÔØBoulder.

For media inquiries, please visit .

Latest News

Visit the Newsroom